Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Placebo (saline)|DRUG: Exemestane|DRUG: Everolimus
Sponsor: Bayer